Literature DB >> 11739502

In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation.

C Roucard1, C Thomas, M A Pasquier, J Trowsdale, J J Sotto, J Neefjes, M van Ham.   

Abstract

Ag presentation via HLA class II molecules in B lymphocytes depends on the coordinated action of HLA-DM, the catalyst of class II-peptide loading, and HLA-DO, a pH-dependent modulator of DM, the expression of which is almost completely restricted to B lymphocytes. The relative expression levels of both class II modulators are critical for the composition of the HLA class II peptide repertoire. The data in this work demonstrate that DO and DM expression are both dependent on the cellular activation status in primary human B lymphocytes. In vivo low-density activated primary human B lymphocytes show a prominent reduction in DO and DM expression when compared with high-density resting primary B lymphocytes. In vitro, reduction of DO and DM expression can be induced by B lymphocyte activation via the B cell receptor or by use of the phorbol ester, PMA. Specific inhibition of protein kinase C resulted in a significant reduction of HLA-DO and is potentially due to protein degradation in lysosomal compartments as the phenomenon is reversed by chloroquine. Thus, the expression of the dedicated HLA class II chaperone DM and its pH-dependent modulator DO is regulated and tightly controlled by the activation status of the B lymphocyte.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739502     DOI: 10.4049/jimmunol.167.12.6849

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  The expression of HLA-DO (H2-O) in B lymphocytes.

Authors:  Xinjian Chen; Peter E Jensen
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  TLR agonists downregulate H2-O in CD8alpha- dendritic cells.

Authors:  Gavin W Porter; Woelsung Yi; Lisa K Denzin
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

3.  Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence.

Authors:  Woelsung Yi; Nilufer P Seth; Tom Martillotti; Kai W Wucherpfennig; Derek B Sant'Angelo; Lisa K Denzin
Journal:  J Clin Invest       Date:  2010-04       Impact factor: 14.808

4.  The MHC class II cofactor HLA-DM interacts with Ig in B cells.

Authors:  Henriette Macmillan; Michael J Strohman; Sashi Ayyangar; Wei Jiang; Narendiran Rajasekaran; Armin Spura; Ann J Hessell; Anne-Marie Madec; Elizabeth D Mellins
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

5.  Genetic variants in major histocompatibility complex-linked genes associate with pediatric liver transplant rejection.

Authors:  Rakesh Sindhi; Brandon W Higgs; Daniel E Weeks; Chethan Ashokkumar; Ronald Jaffe; Cecilia Kim; Patrick Wilson; Nydia Chien; Joseph Glessner; Anjan Talukdar; George Mazariegos; M Michael Barmada; Edward Frackleton; Nancy Petro; Andrew Eckert; Hakon Hakonarson; Robert Ferrell
Journal:  Gastroenterology       Date:  2008-06-03       Impact factor: 22.682

Review 6.  The love and hate relationship of HLA-DM/DO in the selection of immunodominant epitopes.

Authors:  Robin A Welsh; Scheherazade Sadegh-Nasseri
Journal:  Curr Opin Immunol       Date:  2020-06-28       Impact factor: 7.486

7.  Burkitt lymphoma: pathogenesis and immune evasion.

Authors:  Jason M God; Azizul Haque
Journal:  J Oncol       Date:  2010-10-05       Impact factor: 4.375

Review 8.  How Does B Cell Antigen Presentation Affect Memory CD4 T Cell Differentiation and Longevity?

Authors:  Robin A Welsh; Nianbin Song; Scheherazade Sadegh-Nasseri
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

9.  Ubiquitination of HLA-DO by MARCH family E3 ligases.

Authors:  Martin Jahnke; John Trowsdale; Adrian P Kelly
Journal:  Eur J Immunol       Date:  2013-03-11       Impact factor: 5.532

10.  pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity.

Authors:  Wei Jiang; Michael J Strohman; Sriram Somasundaram; Sashi Ayyangar; Tieying Hou; Nan Wang; Elizabeth D Mellins
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.